Navigation Links
Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4,Inhibitor, ARI-2243, at the ADA

- ARI-2243 is an highly potent DPP-4 inhibitor, possessing Ki of 27 pM

BOSTON, June 25, 2007 /PRNewswire/ -- Arisaph Pharmaceuticals, Inc., a privately held drug discovery biopharmaceutical company, announced today the results of its potent, smart DPP-4 inhibitor, ARI-2243, presented at the 67th session of the American Diabetes Association meeting in Chicago, Illinois. The results showed that ARI-2243 is an extremely long acting, potent inhibitor of DPP-4 and produced superior reductions in plasma glucose compared with sitagliptin in oral glucose tolerance test (OGTT) in mice. Additionally, ARI-2243 produced significant reduction in hemoglobin A1c levels (HbA1c) following 9 weeks of daily oral dosing in an highly refractory diabetic animal model compared with no significant change with vildagliptin. The long-acting and potent attributes of ARI-2243 are expected to confer a differentiated efficacy profile in diabetic patients. Arisaph is currently completing IND enabling studies and expects to initiate first-in-man testing in 2008.

Arisaph designed ARI-2243 as a once a day, orally active, smart DPP-4 inhibitor that is highly potent and functionally selective. In vitro kinetic studies show that ARI-2243 has an affinity (Ki) of 27 picomolar, binding tightly to DPP-4 and dissociating very slowly from the enzyme. Such binding kinetics confer potency and long activity. Specifically, during OGTT in normal mice, ARI-2243 produced far greater lowering of plasma glucose compared with sitagliptin. Specifically, the ED50 with ARI-2243 was 0.006 mg/kg compared with sitagliptin, which had an ED50 of 1.5 mg/kg. Moreover, at 18 hours post dose, ARI-2243 lowered plasma AUC 25%, demonstrating long duration of action of the smart inhibitor.

In ZDF rats, an animal model that develops overt diabetes, ARI-2243 produced a significant reduction in HbA1c of 2.5% and 2.2% versus placebo and vildagliptin, respectively follo
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
(Date:7/11/2014)... , July 11, 2014 Research and ... Hypodermic Needles Market 2014-2018" report to their offering. ... A hypodermic needle is a hollow needle commonly used ... or or to extract fluids from it. A hypodermic ... to inject substances that cannot be ingested. Hypodermic needles ...
(Date:7/11/2014)... New York , July 11, 2014 ... by Transparency Market Research "Endoscopy Devices Market (Endoscopes, Endoscopic ... Size, Share, Growth, Trends and Forecast, 2013-2019" the global ... in 2012 and is expected to grow at a ... an estimated value of USD 36.9 billion in 2019. ...
(Date:7/11/2014)... -- Neurelis, Inc. ("Neurelis") today announced an agreement with ... by Biotie to purchase Neurelis, clearing the way for ... for pediatric and adult epilepsy patients who experience acute ... has advanced the development program for NRL-1 and worked ... required for NDA submission to the FDA.  Given the ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
(Date:7/14/2014)... 14, 2014 Sometimes, thinking “inside the ... Playground announces its first product release, Joyboxx™ - The ... system. , Inventor and CEO, Deborah Semer ... have a storage solution for their ‘toys’ after she ... adult retail industry. , Semer met 30-year industry veteran ...
(Date:7/14/2014)... July 14, 2014 The Cabin Chiang ... its new Alumni Community website – a ... to help them maintain lifelong recovery wherever they live ... providing clients the tools to help them maintain their ... essential part of any reputable treatment programme. As a ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 AttorneyOne.com, a ... all the latest information from the FDA on ... The FDA informed on July 11, that one lot ... mL, Flexible Container, by Hospira Inc., is recalled due ... parenteral replacement of extracellular losses of fluid and electrolytes, ...
(Date:7/14/2014)... According to the Blood Pressure Solution book review recently updated ... series of new information on high blood pressure . ... help readers understand more about blood pressure. The book shows ... to control hypertension naturally. , Blood Pressure ... by Ken Burge, a medical researcher and health consultant. Since ...
(Date:7/14/2014)... to the Boost Your Bust book review recently updated by Vkool.com, ... how to increase the size of their breasts naturally without medication ... , Chapter 1 – What Are Your Breasts And ... Natural Breast Enlargement Works , Chapter 3 – The ... 4 – The Groundwork , Chapter 5 – Personal ...
Breaking Medicine News(10 mins):Health News:Passionate Playground launches Joyboxx 2Health News:Passionate Playground launches Joyboxx 3Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 2Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 3Health News:Hospira Lactated Ringer’s and 5% Dextrose Injection Recalled: AttorneyOne Monitor and Keep Consumers Informed 2Health News:Hospira Lactated Ringer’s and 5% Dextrose Injection Recalled: AttorneyOne Monitor and Keep Consumers Informed 3Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 2Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 3Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 2Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 3
... research published in The Lancet states that, consuming a ... faster information processing and memory in the older adults. ... reduced levels of folate, and elevated levels of amino ... restricts cognitive ability, increasing the risk of dementia. ...
... the NHS trust to cater to mental problems afflicting the ... a document enabled by Durham County Council's inquiry committee, recognized ... in Durham and Darlington. The report threw light on the ... problems across six primary care trust areas in the region. ...
... the sake of good health., Students of Pittsburgh’s Plum ... last 10 months; via cafeteria meals. This was announced Thursday. ... by-products such as hulls of oats, soybeans, peas and rice, ... school meals to cut down calories while preserving a favorable ...
... showed reasonable resistance to Tamiflu, an antiviral, in two Egyptians who ... the medical community. ,The report also states that the ... in 2005. The occurrence of this strain in Egypt reveals that ... Tamiflu by the birdflu virus has not changed the WHO stance ...
... for short-term relief of chronic back pain, but their ... by researchers at Yale School of Medicine, who also ... in 24 percent of cases. ,“Patients with ... medications are used despite the concerns clinicians have with ...
... molecule that is part of a complex signaling network ... periventricular heterotopia (PVH), a congenital brain malformation, Yale School ... often leads to a variety of neurological disorders such ... It has many environmental and genetic causes, but is ...
Cached Medicine News:Health News:Long-Term Narcotics Use for Back Pain May Be Ineffective and Lead to Abuse 2Health News:Missing Molecule Has Important Role in a Developmental Brain Abnormality 2
M2 cemented hip stem....
Porous foundation 480 series....
Cemented foundation 460 series....
Porous foundation 440 series....
Medicine Products: